Dawaseva — интернет-аптека с приоритетом дженериков для пациентов с хроническими заболеваниями в Индии

Real comparables: Truemeds (generic substitution, FY25 revenue of 510 crore rupees, average discounts rising from 29% to 32%), Tata 1mg (profitable, about INR 3,000 crore revenue), PharmEasy, Netmeds and Apollo 24|7. The model follows the Truemeds pattern: chronic patients are 60–70% of e-pharmacy order volume, and generics are the only way to fund a deep discount and still keep a margin.

Who pays

Households in Tier-1 and Tier-2 cities paying out of pocket for chronic medicines — the patient or, very often, an adult child ordering for parents. Average monthly spend on medicines at MRP is about ₹1,350 per active customer (Truemeds reports an average order value of 1,000–1,500 rupees). Insurance in India rarely covers outpatient medicines, so the buyer is price-sensitive and loyal once a refill routine is set up.

How it makes money

Retail margin on medicines. The customer pays MRP less an average 20% discount: on ₹1,350 ($15.34 at 88 rupees per dollar) of MRP value a month, that is about $12.27 of net sales. Medicines are bought from distributors and generic manufacturers at an average 54% of MRP (branded at MRP minus 20–25%, generics and private label at MRP minus 60–70%, generics about 60% of the basket), leaving about 26% of MRP as gross margin. Small extras: a delivery fee on orders below 500 rupees and referral commissions from partner diagnostic labs, together about $0.32 per active customer a month. GST on medicines is 5% (since 22 September 2025) and is included in MRP; after input credit on purchases the net GST is about 1.24% of MRP value.

Key assumptions

• Discount and margin: Truemeds raised average discounts from 29% to 32% in a year (TechCrunch, 2025) — the model uses 20% because it does not buy volume with discounts on branded drugs; distributor margins in the market are thin (10–15% for pharmacies selling mainly branded medicines), so the 26% gross margin depends on generics being about 60% of the basket.
• Retention: not every buyer is chronic — one-off acute orders mix in, so 62% reorder in month 2, 25% still order after 12 months, then 2.8% a month leave. One estimate says an e-pharmacy needs about 20 repeat purchases to break even on a customer; the model's average lifetime is shorter, so it keeps paid acquisition at about five to seven dollars per first order including the welcome discount.
• Acquisition at median conversion: Google App Campaigns cost about ₹45 ($0.51) per install, 12% of installs place a first order; Meta at $1.60 CPM, 1.2% CTR, 30% install, 10% order. Doctors' clinics and neighbourhood chemists that pass prescriptions get ₹300 ($3.41) per first order. Every first order carries a ₹150 ($1.70) welcome discount on top of the regular one.
• Fulfilment per order: refills are scheduled, so last-mile delivery is batched into routes at about 42 rupees per order by a 3PL (on-demand delivery costs 55–60); picking, packing and pharmacist verification 12 rupees. With 1.15 orders a month per active customer that is $0.55 and $0.16. Teleconsult e-prescriptions for 30% of orders without a valid prescription cost 30 rupees each ($0.10 per customer). Payment gateway and COD handling 1.2% of MRP value; expiries, returns and breakage 1%.
• Organic search is a real channel here: patients search medicine names and 'substitute for…', and pages per molecule are how Truemeds and 1mg grow; the model keeps organic below half of new customers.
• Bengaluru salaries: senior engineer about ₹3.3 lakh a month ($3,750), engineer ₹1.6 lakh ($1,820), registered pharmacist ₹32,000 ($364), warehouse associate ₹18,000 ($205); employer PF and gratuity add 12%.
• Working capital: hubs hold about 20 days of stock, which the model does not show as a cost. The $1.6M of initial cash covers the modeled operating trough plus that inventory; a 30-day distributor credit line would reduce it.
• Key sensitivity — generics share (60% of the basket in the model): generics are bought at about 35% of MRP and branded drugs at about 78%, so every 10 points of generics share move gross margin by about 4.3% of MRP, $0.66 per active customer a month. At 50% generics the business is near zero, at 45% it loses money. The second lever is scheduled refills: on-demand delivery at 55 rupees instead of routed refills turns NPV negative. Revenue here is retail sales of medicines, so even a modest customer base gives large revenue at a thin net margin; cumulative payback comes late, so the horizon is 60 months.

Risks

• Regulation: e-pharmacy rules under the Drugs and Cosmetics Act have been in draft since 2018, and chemists' associations regularly petition to ban online sales; a restrictive final rule could force licensed retail partners into the chain and cut margin.
• Substitution trust: doctors and patients may refuse generics; if the generic share falls from about half to a quarter of the basket, gross margin falls by roughly a third.
• Discount war: Tata 1mg, PharmEasy, Apollo and quick-commerce players (Zepto, Blinkit) can outspend a newcomer on discounts and 10-minute delivery.
• Quality and compliance: Schedule H/H1 drugs need a valid prescription and record keeping; a single counterfeit or wrong-dispensing incident is a licence and reputation risk.

How to adapt this model

• For a branded-only pharmacy without generics, cut the cost-of-goods line to about 75–78% of MRP and the discount to 12–15%; the business then needs far larger scale and lower delivery cost to make money.
• For quick-commerce delivery (under 30 minutes), raise per-order delivery cost two to three times and add dark-store rent as fixed cost per city; it wins acute (one-off) orders, not chronic refills.
• For Indonesia, the Philippines or Pakistan, change the currency rate, VAT/GST line, delivery cost and the generics share; the chronic-refill mechanic stays the same.
• If you add teleconsultations or diagnostics as a revenue line, keep each attach rate modest (5–10% of customers a month) — no single add-on should carry the profit.

Sources

• Truemeds: discounts 29%→32%, valuation jump: https://techcrunch.com/2025/08/10/truemeds-challenged-how-indians-buy-medicine-and-saw-a-3-6x-jump-in-valuation
• Truemeds FY25 revenue INR 510 Cr, AOV INR 1,000–1,500: https://www.newsbeep.com/au/96028/
• Tata 1mg ~INR 3,000 crore revenue, profitable (The Ken): https://the-ken.com/podcasts/daybreak/why-tata-1mg-thinks-speed-is-the-wrong-bet-in-pharma/
• Thin 10–15% margins for pharmacies and platforms: https://valueforstartups.in/tata1mg
• Chronic patients 60–70% of e-pharma order volume (GlobalData): https://www.globaldata.com/media/pharma/e-pharma-set-revolutionize-drug-market-access-india-covid-19-drives-e-commerce-growth-says-globaldata/
• ~20 repeat purchases to break even on a customer: https://blog.finology.in/startups-india/e-pharmacy
• GST 2.0: medicines 12%→5% from 22 Sep 2025 (PIB): https://static.pib.gov.in/WriteReadData/specificdocs/documents/2025/sep/doc202594628401.pdf